Company profile: SPR Therapeutics
1.1 - Company Overview
Company description
- Provider of advanced peripheral nerve stimulation (PNS) solutions for pain management, including the SPRINT PNS System—a minimally invasive, drug-free 60-day treatment delivering significant and sustained relief from chronic and acute pain without a permanent implant—and training events for interventional pain management physicians on ultrasound and fluoroscopic imaging and hands-on lead implantation using the system.
Products and services
- Peripheral Nerve Stimulation (PNS) Training Events: Ultrasound-guided instruction for interventional pain management physicians on fluoroscopic imaging and hands-on SPRINT PNS System lead implantation procedures to improve procedural proficiency
- SPRINT PNS System: Minimally invasive, 60-day peripheral nerve stimulation treatment delivering significant, sustained relief for chronic and acute pain without a permanent implant and entirely drug-free
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SPR Therapeutics
Flexion Therapeutics
HQ: United States
Website
- Description: Provider of long-lasting intra-articular injection therapies to treat osteoarthritis, and of collaborative drug development services that advance candidates through clinical proof of concept and beyond in partnership with pharmaceutical and biotechnology companies, sharing expertise and risk to help expand partners' portfolios.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flexion Therapeutics company profile →
Assertio
HQ: United States
Website
- Description: Provider of pharmaceutical therapies for pain and inflammation and oncology support, offering Cambia (diclofenac potassium) for acute pain; INDOCIN oral suspension and suppositories (indomethacin); SPRIX nasal spray (ketorolac) for short-term moderate to severe pain; Otrexup (methotrexate) injection for certain cancers and autoimmune diseases; and ROLVEDON to reduce severe neutropenia in chemotherapy patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Assertio company profile →
Concentric Analgesics
HQ: United States
Website
- Description: Provider of non-opioid therapeutics for acute and chronic pain, including Vocacapsaicin (CA-008), a single-administration prodrug for postsurgical pain; CA-051 for epidural treatment of refractory pain associated with cancer or following amputation; and a novel injection for chronic osteoarthritis pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Concentric Analgesics company profile →
Sky Medical Technology
HQ: United Kingdom
Website
- Description: Provider of bioelectronic medicine for vascular-related conditions, offering the geko wearable device powered by OnPulse neuromodulation to stimulate the common peroneal nerve and activate calf and foot muscle pumps, increasing venous, arterial, and microvascular circulation to prevent and treat DVT, post-operative edema, and promote wound healing; includes a Partner-With-Us program for clinician collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sky Medical Technology company profile →
Heron Therapeutics
HQ: United States
Website
- Description: Provider of polymer-based pharmaceuticals for acute and oncology care, offering therapies to reduce postsurgical pain and prevent nausea and vomiting from chemotherapy and surgery. Products include SUSTOL (5-HT3 antagonist), CINVANTI (IV NK1 antagonist), ZYNRELEF (bupivacaine + meloxicam), and APONVIE (IV NK1 antagonist), plus Acute Care Solutions and Oncology Care Solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Heron Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SPR Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SPR Therapeutics
2.2 - Growth funds investing in similar companies to SPR Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SPR Therapeutics
4.2 - Public trading comparable groups for SPR Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →